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 Abstract 
 
Background: To measure suspected abuse of the methamphetamine (MA) among methadone 
maintenance treatment (MMT) patients in Tehran, we studied all 206 patients who were admitted to 
MMT program from 2009 to 2015 to Andishe-No addiction treatment clinic.  
Methods: MA presence was screened in one of the random urine samples routinely taken for tests 
of other drugs.  
Results: 70 (34.3%) patients were positive for MA. A logistic regression (multivariate analyses) 
demonstrated that the MA abusers were more likely to be opiate abusers and less likely to be 
married. 
Conclusion: The high prevalence of MA abuse found in our patients which was rather higher than 
the rate of MA abuse before treatment entrance. The high rate of MA abuse in Iran needs future 
study  
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     Introduction  
      Addiction has always been one of the major 
concerns of every country’s health systems and 
different societies tried to resolve it in many 
ways, such as prison, execution, fighting with 
manufacture and trade illegal drugs, medical and 
non-medical treatments, etc. (1). Based on global 
estimation in 2008, 150-250 millions of people 
(3.5-5.7% of world population) had at least tried 
one illegal drug during life-long, among whom 
16-38 million were “problem drug user” (2).  
World Health Organization (WHO) and American 
Psychiatric Association (APA) defined addiction 
as a chronic disease and related problem with 
severe craving to drugs and tolerance (3).  
Researches indicated that using multi drugs is a 
severe barrier to successful intervention Treatment 
process would be much more complicated if the 
patient uses two or more types of drugs (4, 5). 
Methamphetamine (MA) is the most popular drug 
after cannabis in the world (6). 
 
 
 
 
During the last decade, health services in Iran 
have expanded methadone maintenance treatment 
(MMT) all over the country. As opiates had been 
the drug of choice of the vast majority of drug 
users in Iran, MMT program was successful and 
promising in the drug use treatment network (7). 
Before 2005, there was no available MA in 
Iranian drug market, although it has been used in 
many countries in the past 20 years (8). An 
increase was observed in MA use among MMT 
patients who were stimulant-naive and passed a 
successful MMT period (9, 10). Some reasons 
were proposed for this problem such as side 
effects of methadone on mood and energy level, 
sexual dysfunction and physical activity. Then 
many patients prefer combination of methadone 
and MA. Using both drugs at the same time cause 
an increase in extracellular synaptic dopamine 
level which is much greater than only one drug  
(11). By MA abuse in patients during MMT, 
clinicians are faced a new, unknown situation 
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which can reduce the effectiveness of MMT 
program. 
Cooperation level and maintenance of patients in 
long-term treatment plans such as MMT is one of 
the most vital challenges clinicians are faced 
with. One of the disturbing items during MMT is 
using MA in addition to methadone. In this state, 
it is important to know the rate of MA relapses 
during MMT in patients who mostly had no 
experience of stimulants use before starting 
MMT. Thus, the aim of this study is to evaluate 
the percentage of MA use during MMT in 
addicts.   
We found that MA was abused among MMT 
patients in our addiction treatment clinic based on 
some of patients' self-reports and clinical 
assessment of symptoms. Since this may have 
severe clinical implications for the MMT 
program, we decided to assess the prevalence of 
MA abuse among all patients treated from 2011 
to present in the Andishe-No MMT Clinic in 
Tehran (Iran). 
 
 Methods 
     This analysis was approved by the Ethical 
Review Board of the Behavioral Sciences 
Research Center of Shahid Beheshti University of 
Medical Sciences (ref: 1392-1-91-12607-1). The 
Andishe-No addiction treatment center, admitted 
206 patients from 2009 who met criteria for 
entering methadone maintenance treatment 
(DSM-IV criteria of dependence with multiple 
self-administrations of opiates per day for at least 
one year).  
Patients in MMT undergo repeated observed 
urine tests throughout the entire length of their 
treatment. For the purposes of this study, MA was 
determined for each patient (methamphetamine 
[MET]) that are taken during one month 
randomly for morphine (MOP) and cannabis 
(THC). A positive result was defined by at least 
one of the urine samples testing positive for the 
substance. 
A modified addiction severity index (ASI) and 
other demographic details were retrieved from the 
patients.  
The patients included in the study were chosen 
among those who were in treatment in the 
Andishe-No clinic admitted from 2009 to 2015. 
1. A DSM-IV-TR diagnosis for narcotics 
dependence; 
2. Being in methadone maintenance treatment; 
and 
3. Patient did not refuse to give urine for test. 
    The sample consisted of 206 patients. Their 
mean age was 45 years (range 18-72). The 
majority was male (199, 96%); married (115, 
56%), had relatively medium educational 
levels (11 yrs.), and were employed (176, 
81%). At the time of the study the mean of 
treatment duration was over 2 years. For 61 
(30%), this episode was their first treatment 
attempt. 
All patients entering treatment have an assessment 
performed, which includes socio-demographic 
data, addiction history, medical, and psychosocial 
related variables by Addiction Severity Index 
(ISI).  
A modified Addiction Severity Index (ASI) and 
other socio-demographic details were retrieved 
from the patients' records that are part of the 
routine intake upon entry to the clinic, including 
lifetime psychiatric diagnoses, drug abuse history, 
etc. 
1) Addiction Severity Index: ASI is a semi-
structured interview for substance abuse 
assessment and treatment planning (12). The ASI 
was the first standardized assessment tool of its 
kind to measure the multiple dimensions of 
substance abuse. It has three categories: 1) socio-
demographic: gender, age, years of education, 
and main source of income; 2) consumption: 
main substance, type of treatments, years of 
consumption; and 3) severity of dependency. 
Overall, studies typically conclude that the 
Addiction Severity Index is a consistent and 
accurate tool for assessing clients and their 
substance abuse issues. The ASI is able to 
successfully identify the client’s problem area in 
which they are experiencing the greatest 
difficulties, such as alcohol or drug addiction, or 
legal or familial problems. Once a client’s 
psycho-social issues are identified, an appropriate 
course of treatment may be administered. 
Severity ratings are based on the following 10 
point scale (0-9): 
0-1 No real problem, treatment not indicated 
2-3 Slight problems, treatment probably not 
necessary 
4-5 Moderate problem, some treatment indicated 
6-7 Considerable problems, treatment necessary 
Noorbakhsh, Roohi, Farrahi 
 
International Journal of Applied Behavioral Sciences (IJABS) volume 2 number 3 summer 2015. Journals. smbu.ac.ir/ijabs                  31 
 
 8-9 Extreme problems, treatment absolutely 
necessary 
The severity ratings scale allows for the 
interviewer to determine the seriousness of a 
client’s problem. The higher the score is, the 
greater the need for treatment in each area or 
immediate intervention. The ASI scores can be 
used to profile a client’s problem areas and then 
plan an effective course of treatment (13).   
Data analyzes were done using the SPSS-21 
software. Results were compared using the Chi-
square or Fisher's Exact test in categorical 
variables and one-way analysis of variance 
(ANOVA) in continuous variables. Logistic 
regression model for positive urine of MA was 
done with all variables that were found to be 
significant (pb0.05) in the univariate analyses.  
 
Results 
Prevalence of MA 
The percentage of MA use before and after 
treatment is as presented below. 
 
Table 1. Prevalence of used drugs before treatment 
Drug Frequency Percent 
Narcotic 140 68.6 
Methamphetamine 63 30.9 
Others (alcohol, THC, etc) 2 0.5 
Total 206 100 
 
 
Table 2. The percentage of MA positive and negative urine tests 
Drug Frequency Percent 
MA positive test 70 34.3 
MA negative test 115 56.4 
missing 21 9.3 
Total 206 100 
 
A total of 70 (34.3%) of the 206 study participants 
were tested positive for MA in Tehran, which was 
30.9 before starting treatment.  
MA abusers and non-abusers  
Patients with urine tests positive or negative for 
MA did not differ in age (38 years vs. 49, years, 
respectively,P=0.06), duration of MMT (37 
months vs. 23 months, P=0.79), previously being 
treated for addiction (P= 0.17), job (P= 0.19), and 
educatio (P=0.08). However, two groups revealed 
some significant differences in the rate of urine 
samples that tested positive for opiates (P= 0.00), 
using counseling facilities (P=0.00), and marital 
status (P=0.01). 
Multivariate analyses 
A logistic regression (multivariate analyses) 
demonstrated that the MA abusers were more 
likely to be opiate abusers (OR= 4.9, 95% CI 2.4–
10.1) and less likely to be married (OR= 0.85 
95% CI 0.75–0.97). 
 
 Conclusion 
      Opioids have been used by Iranians for 
centuries but methamphetamine (MA) is a newly 
introduced psycho-stimulant drug in Iran, which 
is characterized by highly addictive effects. MA 
which is informally named Shisheh has been 
changed in to an epidemic drug of choice among 
MMPTs. There is a dearth of research on MA use 
and dependence in Iran (14). Methamphetamine 
is known as a synthetic derivative of amphetamine, 
but due to the addition of a methyl group in its 
chemical structure, it has lipid solubility, allowing 
more rapid transport of the drug across the blood–
brain barrier (15). The most frequent and usual 
symptoms among Iranian MA users were 
delusions, mood instability, disorientation, and 
self-mutilation (16), also prevalent psychotic 
symptoms were persecutory delusions (82%), 
auditory hallucinations (70%), reference delusions 
(57%), visual hallucinations (44%), grandiosity 
delusions (39%) and jealousy delusions (26%) 
(17). Because of heavy use, many of such cases 
are characterized by delusions, hallucinations, 
anxiety, insomnia, mood disturbances, suicide, 
violent behaviors and homicidal ideations (18). 
This is consistent with some studies in other 
countries which indicate that heavy use of 
methamphetamine contributes to a variety of 
severe psychiatric problems (19). 
Continued drug abuse during MMT represents a 
complication and, perhaps, a partial failure of 
MMT. As such, it be worthy of more attention. 
We studied the additional abuse methamphetamine 
– the most frequently abused drug in our 
population of Opioids individuals - having 
assessed the 206 study patients over a 5-year 
period. All our study patients were Opioids 
dependent and started their MMT as Opioids 
users during the 5-year period from 2009 to 2014. 
The high rate (34.3%) of MA abuse found among 
our patients. In the Andishe-No center, the abuse 
of MA was also found in the multivariate analyses 
to characterize narcotic abusers with fewer tare of 
marriage.  
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The primary clinical syndrome of MA overdose 
involves prominent neurological and cardiovascular 
effects, while secondary complications can involve 
renal, muscle, pulmonary, and gastrointestinal 
effects. In overdose, the patient may present with 
mydriasis, tremor, agitation, hyperreflexia, 
combative behavior, confusion, hallucinations, 
delirium, anxiety, paranoia, movement disorders, 
and seizures (20). It could be possible that MA 
may also be used for “management” (by the 
patients themselves) of opiate-induced- and 
sedative-induced sedation, meaning that MA use 
might also serve as a means to reduce drowsiness 
resulting from narcotics (including methadone) 
(10). This is consistent with the finding that the 
MA group, as compared to no MA users group 
was more likely to use narcotics as well. 
A future study evaluating the motives, 
circumstances and patterns of MA intake by 
patients will add insight into the phenomenon. 
Such a study however, would necessitate 
informing patients and would require high 
sensitivity and specificity methodology for the 
detection of MA.  
Clinical observations show an increase in 
methamphetamine use among stimulant-naive 
successful MMT clients. Methamphetamine could 
be an attractive drug to ameliorate some of the 
side-effects of methadone on psychological energy, 
sexual functioning and cognitive performance. 
Not providing effective adjuvant psychological 
and behavioral interventions to address 
methamphetamine use (as is the current situation 
in Iranian MMT clinics) may undermine the 
benefits of MMT (9). 
Globally, no pharmacological treatment has been 
approved for the treatment of MA use. Medications 
such as antidepressants, dopamine agonists and 
antagonists have been tried for their clinical 
effectiveness in managing MA withdrawal or 
dependence (21). In Iran, psychiatric medications 
are prescribed to manage acute and severe MA 
use presentations such as MA intoxication and 
psychosis. Several medications such as Bupropion 
(22), Baclofen (23), Topiramate (24), and 
Naltrexone (25) have been suggested for the 
treatment of MA use and dependence but non-
pharmacological treatments have remained as the 
best practice. Non-pharmacological treatment 
interventions for MA use include brief 
interventions, behavioral therapies, psychosocial 
therapies, residential rehabilitation, and 12-step 
programs. 
Psychosocial therapies generally manipulate 
elements of education and the social environment 
to help patients recover from MA use and 
dependence. These therapies include cognitive 
behavioral therapy (CBT) (including the Matrix 
model of intensive outpatient treatment) and 
motivational interviewing (MI). The Matrix 
model includes elements of social learning, 
psychological education, and social support with 
CBT principles (26). In the largest trial of a 
treatment for MA-dependent clients in America, 
patients randomly assigned to receive the Matrix 
model treatment demonstrated better ability for 
retention in treatment, in producing more free 
urine samples and in achieving extended periods 
of abstinence compared with patients assigned to 
receive “treatment as usual” (27). The Matrix 
model is the most common outpatient treatment 
for MA use and dependence in Iran. It has 
received clinical attention and is implemented by 
psychotherapists and clinical psychologists at 
outpatient drug use treatment clinics in some 
large cities of Iran including Tehran. It should be 
noted that the national protocol of MA use 
treatment is being devised based on the Matrix 
model in Iran. A considerable number of Iranian 
MA-dependent patients receive the Matrix model 
but the clinical effectiveness of the Matrix model 
as an American model of MA use treatment has 
not been fully evaluated for Iranian MA-using 
population. MI is another form of psychosocial 
treatment. One important concept of MI is that 
the treatment is designed for patients to progress 
along the stages of change, assuming sole 
responsibility for their decisions about drug use 
(28). MI is one of the best implemented treatment 
interventions in Iran which contributes to 
increasing MA patients’ motivations to change 
and treatment adherence. MI is applied at 
outpatient addiction centers and it is an important 
part of long-term outpatient treatment of MA-
dependent patients in the country. A considerable 
number of Iranian MA-dependent patients receive 
MI before initiating treatment with the Matrix 
model but there is a paucity of research on MI 
and its clinical effectiveness in Iran. 
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